Exact Sciences Corp
NASDAQ:EXAS
If you don’t study any companies, you have the same success buying stocks as you do in a poker game if you bet without looking at your cards.
Utilize notes to systematically review your investment decisions. By reflecting on past outcomes, you can discern effective strategies and identify those that underperformed. This continuous feedback loop enables you to adapt and refine your approach, optimizing for future success.
Each note serves as a learning point, offering insights into your decision-making processes. Over time, you'll accumulate a personalized database of knowledge, enhancing your ability to make informed decisions quickly and effectively.
With a comprehensive record of your investment history at your fingertips, you can compare current opportunities against past experiences. This not only bolsters your confidence but also ensures that each decision is grounded in a well-documented rationale.
Do you really want to delete this note?
This action cannot be undone.
| 52 Week Range |
41.33
75.72
|
| Price Target |
|
We'll email you a reminder when the closing price reaches USD.
Choose the stock you wish to monitor with a price alert.
This alert will be permanently deleted.
Exact Sciences Corp
Exact Sciences Corp
Other Operating Expenses
Exact Sciences Corp
Other Operating Expenses Peer Comparison
Competitors Analysis
Latest Figures & CAGR of Competitors
| Company | Other Operating Expenses | CAGR 3Y | CAGR 5Y | CAGR 10Y | ||
|---|---|---|---|---|---|---|
|
|
Exact Sciences Corp
NASDAQ:EXAS
|
Other Operating Expenses
$13m
|
CAGR 3-Years
N/A
|
CAGR 5-Years
N/A
|
CAGR 10-Years
N/A
|
|
|
Abbvie Inc
NYSE:ABBV
|
Other Operating Expenses
$0
|
CAGR 3-Years
N/A
|
CAGR 5-Years
N/A
|
CAGR 10-Years
N/A
|
|
|
Gilead Sciences Inc
NASDAQ:GILD
|
Other Operating Expenses
N/A
|
CAGR 3-Years
N/A
|
CAGR 5-Years
N/A
|
CAGR 10-Years
N/A
|
|
|
Amgen Inc
NASDAQ:AMGN
|
Other Operating Expenses
-$189m
|
CAGR 3-Years
-4%
|
CAGR 5-Years
-99%
|
CAGR 10-Years
N/A
|
|
|
Vertex Pharmaceuticals Inc
NASDAQ:VRTX
|
Other Operating Expenses
$49.6m
|
CAGR 3-Years
336%
|
CAGR 5-Years
N/A
|
CAGR 10-Years
N/A
|
|
|
Regeneron Pharmaceuticals Inc
NASDAQ:REGN
|
Other Operating Expenses
-$37.4m
|
CAGR 3-Years
N/A
|
CAGR 5-Years
N/A
|
CAGR 10-Years
N/A
|
|
Exact Sciences Corp
Glance View
Exact Sciences Corp. is a pioneering diagnostics company that focuses on the early detection and prevention of colorectal cancer, which is one of the deadliest cancers in the world. Founded in 1995 and based in Madison, Wisconsin, Exact Sciences made significant strides with its flagship product, Cologuard, the first non-invasive stool-based DNA test approved by the FDA for colorectal cancer screening. By combining advanced molecular biology and genetic testing, the company aims to enhance the efficiency and effectiveness of cancer screening processes, ultimately saving lives and reducing healthcare costs. This innovation has positioned Exact Sciences as a leader in preventive healthcare, catering to the growing demand for accessible and reliable cancer screening solutions in the U.S. and beyond. As the company expands its product portfolio, it is also actively working on additional tests to detect other types of cancers and diseases, demonstrating its commitment to broadening its impact in the health sector. Exact Sciences has engaged in strategic collaborations and acquisitions to accelerate growth and innovation, including partnerships with large biopharmaceutical companies and healthcare providers. For investors, Exact Sciences presents a compelling opportunity—a company at the forefront of a vital healthcare sector, with proven products, a robust pipeline, and a mission that resonates with the increasing emphasis on preventive medicine. With strong revenue growth and a dedicated focus on research and development, Exact Sciences is poised for a future where early intervention and personalized care become the norm.
See Also
What is Exact Sciences Corp's Other Operating Expenses?
Other Operating Expenses
13m
USD
Based on the financial report for Sep 30, 2024, Exact Sciences Corp's Other Operating Expenses amounts to 13m USD.
What is Exact Sciences Corp's Other Operating Expenses growth rate?
Other Operating Expenses CAGR 1Y
-82%
Over the last year, the Other Operating Expenses growth was -82%.
You don't have any saved screeners yet
